Effect of cefodizime (HR 221) on immunological defects induced by surgical stress

Cefodizime, a new aminothiazolylcephalosporin, has been shown to possess immunomodulating activity in many experimental models in vivo and in vitro. The in-vivo effect of the drug was evaluated in a model represented by the surgical patient, being surgical practices usually associated with an immunological impairment involving many aspects of the immune response. Two groups of ten subjects were treated respectively with cefodizime (2g. i.v. daily) and another cephalosporin (ceftriaxone) at the same dosage